Released Feb 28, 2024, after the close
10-K filed Mar 1, 2024, 61 days after period end · 0000950170-24-023845
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$28.19M$28.19M derived+4.3% vs Q4 2022+11.1% vs Q3 2023
Net Income-$19.78M-$19.78M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$13,413,000—
Operating Incomederived-$21,386,000N/M
Operating Cash Flowderived-$14,061,000N/M
Free Cash Flowderived-$14,139,000N/M
Margins · derived
Gross margin47.6%
Operating margin-75.9%+2.3 pt vs Q4 2022
Net margin-70.2%+7.0 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $28.19M | $27.02M | $38.27M | $44.61M |
| Net Income | -$19.78M | -$20.85M | -$9.43M | -$18.03M |
| EPS Diluted | — | — | — | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR